Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment

M. G. Kris, Richard J. Gralla, D. P. Kelsen, E. S. Casper, M. T. Burke, J. J. Fiore, I. R. Cibas, R. T. Heelan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Ninety patients with stage-3 non-small cell lung cancer were given vindesine (3 mg/sq m) plus mitomycin (10 mg/sq m). Data on response are available for 84 adequately treated individuals (93 per cent). For patients who had received no prior chemotherapy, the rate of major objective response was 36 percent (20/55). For previously treated patients the rate of major response was 17 percent (5/29). The drugs were routinely administered in the outpatient department without difficulty. Moderate or severe myelosuppression, neurotoxic, nephrotoxic, or pulmonary toxic effects, nausea, and vomiting occurred in less than 15 percent of all studied patients. Three-drug extravasation ulcerations occurred in 1,129 administrations of chemotherapy (0.3 percent). There were treatment-related deaths, one from sepsis and one from the combination of mitomycin-induced pulmonary and renal toxic effects. The combination of vindesine plus mitomycin is an active, well-tolerated outpatient regimen for patients with non-small cell lung cancer who have not previously received chemotherapy. Further trials are warranted to compare this regimen to other active combinations and to use it as a component of a program of treatment using alternating regimens of chemotherapy.

Original languageEnglish (US)
Pages (from-to)368-372
Number of pages5
JournalChest
Volume87
Issue number3
StatePublished - 1985
Externally publishedYes

Fingerprint

Vindesine
Mitomycin
Non-Small Cell Lung Carcinoma
Outpatients
Drug Therapy
Poisons
Therapeutics
Lung
Pharmaceutical Preparations
Nausea
Vomiting
Sepsis
Kidney

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Kris, M. G., Gralla, R. J., Kelsen, D. P., Casper, E. S., Burke, M. T., Fiore, J. J., ... Heelan, R. T. (1985). Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. Chest, 87(3), 368-372.

Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. / Kris, M. G.; Gralla, Richard J.; Kelsen, D. P.; Casper, E. S.; Burke, M. T.; Fiore, J. J.; Cibas, I. R.; Heelan, R. T.

In: Chest, Vol. 87, No. 3, 1985, p. 368-372.

Research output: Contribution to journalArticle

Kris, MG, Gralla, RJ, Kelsen, DP, Casper, ES, Burke, MT, Fiore, JJ, Cibas, IR & Heelan, RT 1985, 'Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment', Chest, vol. 87, no. 3, pp. 368-372.
Kris MG, Gralla RJ, Kelsen DP, Casper ES, Burke MT, Fiore JJ et al. Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. Chest. 1985;87(3):368-372.
Kris, M. G. ; Gralla, Richard J. ; Kelsen, D. P. ; Casper, E. S. ; Burke, M. T. ; Fiore, J. J. ; Cibas, I. R. ; Heelan, R. T. / Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. In: Chest. 1985 ; Vol. 87, No. 3. pp. 368-372.
@article{a43574790c3e44da9e443a804fe4aa87,
title = "Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment",
abstract = "Ninety patients with stage-3 non-small cell lung cancer were given vindesine (3 mg/sq m) plus mitomycin (10 mg/sq m). Data on response are available for 84 adequately treated individuals (93 per cent). For patients who had received no prior chemotherapy, the rate of major objective response was 36 percent (20/55). For previously treated patients the rate of major response was 17 percent (5/29). The drugs were routinely administered in the outpatient department without difficulty. Moderate or severe myelosuppression, neurotoxic, nephrotoxic, or pulmonary toxic effects, nausea, and vomiting occurred in less than 15 percent of all studied patients. Three-drug extravasation ulcerations occurred in 1,129 administrations of chemotherapy (0.3 percent). There were treatment-related deaths, one from sepsis and one from the combination of mitomycin-induced pulmonary and renal toxic effects. The combination of vindesine plus mitomycin is an active, well-tolerated outpatient regimen for patients with non-small cell lung cancer who have not previously received chemotherapy. Further trials are warranted to compare this regimen to other active combinations and to use it as a component of a program of treatment using alternating regimens of chemotherapy.",
author = "Kris, {M. G.} and Gralla, {Richard J.} and Kelsen, {D. P.} and Casper, {E. S.} and Burke, {M. T.} and Fiore, {J. J.} and Cibas, {I. R.} and Heelan, {R. T.}",
year = "1985",
language = "English (US)",
volume = "87",
pages = "368--372",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment

AU - Kris, M. G.

AU - Gralla, Richard J.

AU - Kelsen, D. P.

AU - Casper, E. S.

AU - Burke, M. T.

AU - Fiore, J. J.

AU - Cibas, I. R.

AU - Heelan, R. T.

PY - 1985

Y1 - 1985

N2 - Ninety patients with stage-3 non-small cell lung cancer were given vindesine (3 mg/sq m) plus mitomycin (10 mg/sq m). Data on response are available for 84 adequately treated individuals (93 per cent). For patients who had received no prior chemotherapy, the rate of major objective response was 36 percent (20/55). For previously treated patients the rate of major response was 17 percent (5/29). The drugs were routinely administered in the outpatient department without difficulty. Moderate or severe myelosuppression, neurotoxic, nephrotoxic, or pulmonary toxic effects, nausea, and vomiting occurred in less than 15 percent of all studied patients. Three-drug extravasation ulcerations occurred in 1,129 administrations of chemotherapy (0.3 percent). There were treatment-related deaths, one from sepsis and one from the combination of mitomycin-induced pulmonary and renal toxic effects. The combination of vindesine plus mitomycin is an active, well-tolerated outpatient regimen for patients with non-small cell lung cancer who have not previously received chemotherapy. Further trials are warranted to compare this regimen to other active combinations and to use it as a component of a program of treatment using alternating regimens of chemotherapy.

AB - Ninety patients with stage-3 non-small cell lung cancer were given vindesine (3 mg/sq m) plus mitomycin (10 mg/sq m). Data on response are available for 84 adequately treated individuals (93 per cent). For patients who had received no prior chemotherapy, the rate of major objective response was 36 percent (20/55). For previously treated patients the rate of major response was 17 percent (5/29). The drugs were routinely administered in the outpatient department without difficulty. Moderate or severe myelosuppression, neurotoxic, nephrotoxic, or pulmonary toxic effects, nausea, and vomiting occurred in less than 15 percent of all studied patients. Three-drug extravasation ulcerations occurred in 1,129 administrations of chemotherapy (0.3 percent). There were treatment-related deaths, one from sepsis and one from the combination of mitomycin-induced pulmonary and renal toxic effects. The combination of vindesine plus mitomycin is an active, well-tolerated outpatient regimen for patients with non-small cell lung cancer who have not previously received chemotherapy. Further trials are warranted to compare this regimen to other active combinations and to use it as a component of a program of treatment using alternating regimens of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0021905703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021905703&partnerID=8YFLogxK

M3 - Article

C2 - 2982552

AN - SCOPUS:0021905703

VL - 87

SP - 368

EP - 372

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -